Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17250
Corporate User License Price USD 750
Corporate User License Price INR 51750
Site License Price USD 500
Site License Price INR 34500
Request a Quote

Report Title

UniQure NV (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

UniQure NV (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

UniQure NV (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

UniQure NV (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies using its gene technology platform. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia A and B, Huntington's disease, congestive heart failure and other research targets. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, the Netherlands.

UniQure NV (QURE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

UniQure NV, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

UniQure Acquires Patents from University of Padova 12

Venture Financing 13

uniQure Raises Additional USD10 Million in Venture Debt Financing 13

uniQure Raises USD 10 Million In Venture Financing 14

UniQure Raises USD17.5 Million in Venture Financing 15

Partnerships 16

Bristol-Myers Squibb Enters into Agreement with uniQure 16

Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 17

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 18

Licensing Agreements 19

uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 19

uniQure Enters into Licensing Agreement with Protein Sciences 20

uniQure Enters into Licensing Agreement with Cold Spring Harbor Laboratory 21

Treeway Enters into Licensing Agreement with uniQure 22

Benitec Biopharma Enters Into Licenising Agreement With uniQure 23

uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 24

Equity Offering 25

uniQure Raises USD147.5 Million in Public Offering of Shares 25

uniQure Raises USD91.2 Million in Public Offering of Shares 27

uniQure Raises USD38 Million in Private Placement of Shares 29

uniQure Raises USD88.5 Million in Public Offering of Shares 30

uniQure Completes IPO For USD 91.8 Million 32

InoCard Spin Out from University of Heidelberg 34

uniQure Announces Private Placement Of Shares For USD 7.8 Million 35

Acquisition 36

UniQure Acquires InoCard for USD5.7 Million 36

uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 37

UniQure NV-Key Competitors 39

UniQure NV-Key Employees 40

UniQure NV-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Nov 06, 2018: uniQure announces third quarter 2018 financial results and highlights company progress 42

Aug 08, 2018: uniQure announces second quarter 2018 financial results and highlights company progress 44

Apr 30, 2018: uniQure Reports First Quarter 2018 Financial Results 47

Mar 14, 2018: uniQure Announces 2017 Financial Results and Recent Company Progress 49

Nov 01, 2017: uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress 51

Aug 08, 2017: uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress 54

May 09, 2017: uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress 56

Mar 15, 2017: uniQure Announces 2016 Financial Results and Provides Update on Company Progress 58

Jan 25, 2017: uniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs 60

Corporate Communications 61

Jun 13, 2018: uniQure Announces New Appointments to its Board of Directors 61

Dec 11, 2017: uniQure Added to NASDAQ Biotechnology Index 62

Aug 07, 2017: uniQure Announces Leadership Team Appointments and Nominations to its Board of Directors 63

Jun 06, 2017: uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer 65

Product News 66

12/09/2017: uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting 66

11/01/2017: uniQure Announces Presentations at the 59th American Society of Hematology Annual Meeting 67

07/21/2017: uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program 69

07/11/2017: uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies 70

07/10/2017: uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B 71

06/23/2017: uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis Congress 73

Jun 15, 2017: uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies 74

May 11, 2017: uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates 75

04/24/2017: uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy 76

04/04/2017: uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System 77

02/06/2017: uniQure Announces Presentations at Upcoming February Conferences 78

Product Approvals 79

Apr 25, 2017: uniQure Receives European Medicines Agency Priority Medicines Designation for AMT-060 in Hemophilia B 79

Jan 30, 2017: uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B 80

Clinical Trials 81

Oct 19, 2017: uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 81

May 10, 2017: uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates 83

Apr 26, 2017: uniQure Presents New Preclinical Data on AMT-130 in Huntington's Disease at CHDI's 12th Annual Huntington's Disease Therapeutics Conference 84

Other Significant Developments 85

Jan 08, 2018: uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value 85

Jan 09, 2017: uniQure Outlines Key Initiatives for 2017 and Vision for 2018 87

Appendix 88

Methodology 88

About GlobalData 88

Contact Us 88

Disclaimer 88

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

UniQure NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

UniQure NV, Deals By Therapy Area, 2012 to YTD 2018 9

UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

UniQure Acquires Patents from University of Padova 12

uniQure Raises Additional USD10 Million in Venture Debt Financing 13

uniQure Raises USD 10 Million In Venture Financing 14

UniQure Raises USD17.5 Million in Venture Financing 15

Bristol-Myers Squibb Enters into Agreement with uniQure 16

Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 17

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 18

uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 19

uniQure Enters into Licensing Agreement with Protein Sciences 20

uniQure Enters into Licensing Agreement with Cold Spring Harbor Laboratory 21

Treeway Enters into Licensing Agreement with uniQure 22

Benitec Biopharma Enters Into Licenising Agreement With uniQure 23

uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 24

uniQure Raises USD147.5 Million in Public Offering of Shares 25

uniQure Raises USD91.2 Million in Public Offering of Shares 27

uniQure Raises USD38 Million in Private Placement of Shares 29

uniQure Raises USD88.5 Million in Public Offering of Shares 30

uniQure Completes IPO For USD 91.8 Million 32

InoCard Spin Out from University of Heidelberg 34

uniQure Announces Private Placement Of Shares For USD 7.8 Million 35

UniQure Acquires InoCard for USD5.7 Million 36

uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 37

UniQure NV, Key Competitors 39

UniQure NV, Key Employees 40

UniQure NV, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

UniQure NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person